Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period

NCT05101317 is registered in ClinicalTrials.gov with Hope Medicine (Nanjing) Co., Ltd as lead sponsor.

NCT NCT05101317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05101317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period
Lead sponsor
Hope Medicine (Nanjing) Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
October 11, 2021
Completion date
March 19, 2025
Enrollment
142 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis